Medical AI Alliance
← Company Index
Pharma & CDMOKOSDAQ 0419601 approvals2 trials

KOMIPHARM INTERNATIONAL CO., LTD.

Official website

Founded in 1972 and listed on KOSDAQ in 2001, Komipharm develops veterinary vaccines and the human anticancer drug PAX-1, including an African swine fever vaccine.

As of 2026-10-10, KOMIPHARM INTERNATIONAL CO., LTD. has 1 Korean MFDS drug approval, 25 PubMed-indexed papers on record (counted by the MAA Company Index from its own matching of public databases).

Price

Change

Market cap

Products & technology

  • PAX-1 (Comenox)Anticancer, cancer-pain, and antiviral treatment
  • Pro-vac PED-FcPorcine epidemic diarrhea vaccine

Regulatory approvals

data.go.kr

1 Korean MFDS drug approvals · 2017

  • MFDS drug코미아스피린정(수출용)2017-04-27
    Drug · OTC · Notification201702179

Clinical trials

data.go.kr

2 MFDS clinical trial authorisations · 2012–2022 (Phase 2 2)

  • Phase 2Panaphix(PAX-1)2022-11-01

    3 trial sites

  • Phase 2KOMINOX2012-12-28

    2 trial sites

R&D and key agreements

Source: DART corporate disclosure

PAX-1 교모세포종 · 교모세포종(뇌암) · 임상2상 완료(호주·한국), 2b상 확대임상 준비중 · Completed Phase 2 glioblastoma trials in Australia and Korea and is preparing an expanded Phase 2b trial with more participants.

PAX-1 말기암 통증치료 · 말기암 환자 마약성진통제 저감·대체 · 임상2상 완료(대만·엘살바도르), 다국가 2b상 인허가심사중 · Completed Phase 2 trials in Taiwan and El Salvador and is analyzing results; an open-label Phase 2 trial in hospice patients is under way in El Salvador, and a multinational Phase 2b trial with an extended 8-week dosing period is under regulatory review.

PAX-1 뇌전이암 · 뇌전이암 · 미국 FDA 임상1/2상 승인, 개시준비중 · Received FDA approval for a Phase 1/2 trial for brain-metastasis treatment in the US and is preparing to begin it.

ASF 약독화 생백신 · 아프리카돼지열병(ASF) · 필리핀 야외임상시험 진행중(2026년 7월 종료 목표) · Developed both an injectable and an oral (bait) vaccine in collaboration with Korea's Animal and Plant Quarantine Agency, the National Wildlife Disease Control Institute, and Chonbuk National University's Institute of Zoonotic Disease Research; 13 domestic laboratory trials met all safety criteria. Related research was published in Animals (MDPI) in January 2025 and in Transboundary and Emerging Diseases (Wiley) in July 2025.

Key disclosures

KRX KIND via OpenDART

Publications

PubMed · affiliation-matched
Show 15 more publications

Patents

KIPRIS · applicant-matched
Show 49 more patents

AI reads

MAA server logs · IP-verified
102
Times AI engines pulled KOMIPHARM INTERNATIONAL CO., LTD.'s records

Pulled records become part of each AI's index and keep feeding its answers. When an AI cites from that index, nothing reaches our server — so actual citations are uncounted here and exceed this number.

18
Fetched fresh mid-answer

Times an AI needed something not yet in its index and fetched this page fresh while answering. Citations served from the index leave no trace here.

84
Index crawls

Collected as raw material for future answers.

0
Direct AI-tool queries (MCP)

Queries from users who connected this index to their own AI.

13
live 1
Last 7 days
61
live 4
Last 30 days
102
live 18
All time
  • OpenAIChatGPT-Userlive18
  • OpenAIOAI-SearchBot68
  • PerplexityPerplexityBot9
  • GoogleGoogleOther3
  • MicrosoftBingbot2
  • AnthropicClaudeBot2

Measured since Aug 25, 2026 · 5 AI engines · last read Oct 10, 2026

User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS. MCP queries are actual calls to this index's tool endpoint.

Connect this index to your AI tool →

Connect this company index directly to your AI

Connect it to ChatGPT or Claude, and your AI queries the full record — profiles, financials, stock data, regulatory approvals, clinical trials, publications and patents — for KOMIPHARM INTERNATIONAL CO., LTD. and every listed Korean medical, bio and AI company.

How to connect (MCP)
Not yet compiled: business overview. Send us materials and we will add them

Companies in the same categoryPharma & CDMO

ILDONG HOLDINGS CO.,LTD100

Founded in 1941 and listed on the KOSPI in 1975, Ildong Holdings is the holding company of the Ildong Pharmaceutical Group, overseeing pharmaceutical, aesthetic medical device, and drug development affiliates.

Yuyu Pharma, Inc.100

Founded in 1941 and listed on the KOSPI in 1975, Yuyu Pharma is a pharmaceutical company with a co-promotion agreement with Dong-A ST for Tanamin.

IL DONG PHARMACEUTICAL CO., LTD.100

Founded and listed on the KOSPI in 2016, Il Dong Pharmaceutical manufactures products including the Aronamin vitamin line.

Medy-Tox Inc.99

Founded 2000, KOSDAQ-listed 2009, Medy-Tox develops and exports botulinum toxin biopharmaceuticals including Meditoxin and Innotox.

GC Biopharma Corp.97

KOSPI-listed comprehensive pharmaceutical company specializing in blood products and vaccines, with FDA-approved immunoglobulin ALYGLO.

DAEWON PHARMACEUTICAL CO.,LTD85

KOSPI-listed pharmaceutical company behind Coldwon cold medicine and Jangdaewon probiotics, developing a P-CAB drug pipeline.

SAMSUNG BIOLOGICS CO.,LTD.85

Founded 2011, listed 2016 — Samsung Biologics is a biopharma CDMO with 785,000L capacity across five Songdo plants.

GENOLUTION INC.85

Founded in 2006 and listed on KOSDAQ in 2020, Genolution is a molecular diagnostics and RNAi company producing nucleic acid extraction reagents and devices.

AHN-GOOK PHARMACEUTICAL Co., Ltd.85

Ahn-Gook Pharmaceutical sells the cough/expectorant drug Sinecuran and the eye-health supplement Tobicom.

CORESTEMCHEMON Inc.85

Founded in 2003 and listed on KOSDAQ in 2015, Corestem Chemon develops stem cell therapies and provides nonclinical CRO services, including the ALS treatment Neuronata-R.

BIO-FD&C CO.,LTD.85

Founded 2005, KOSDAQ-listed 2022, BIO-FD&C develops plant-cell platform-based cosmeceutical materials and biopharma pipelines.

HANDOK Inc.85

KOSPI-listed comprehensive pharma company behind Amaryl diabetes drug and the USD 86.25M HL5101 anticancer out-license deal.

Sources and updates

Counts on this page are not company-reported figures. MAA matched records from DART, the Korean MFDS, the US FDA, ClinicalTrials.gov, PubMed and KIPRIS to this company itself, by business registration number or registered name, never by name similarity. They may differ from figures the company publishes.

Company basics
Korea Exchange · DART
Business content
Compiled from disclosure filings
Approvals & clinical trials
Korean MFDS (data.go.kr) · US FDA openFDA — updated weekly
Key disclosures
KRX KIND via OpenDART exchange filings — updated daily
Global clinical trials
ClinicalTrials.gov (US NIH) — sponsor-matched, updated weekly
Financials
DART corporate disclosure filings — annual
Publications
PubMed (US National Library of Medicine) — affiliation-matched, updated daily
Patents
KIPRIS (Korea Institute of Patent Information) — applicant-matched, updated monthly
AI reads
Our server logs, IP-verified every 6 hours
AI visibility
Measured 2026-10-01

This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.

Request a correction or addition